Clinically, we anticipate that inhibiting intracellular/nuclear MMP‐2 and allowing CHK/MATK re‐expression will enhance the effectiveness of sublethal doxorubicin treatments in osteosarcoma patients. The gene discussed is MMP2; the disease is osteosarcoma.